NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$152.49

From 52W high−21.17%

Volume2.67M

Market cap$14.86B

P/E (TTM)20.7x

P/S (TTM)4.4x

Div yield—

Key dataSep 18, 2026

Open

$152.49

From 52W high

−21.17%

Volume

2.67M

Market cap

$14.86B

ValuationView details →

P/E (Fwd)

17.3x

EV/EBITDA

16.2x

P/E (TTM)

20.7x

RSI (14)

36.2

MomentumView details →

1D Return

−3.69%

YTD Return

+4.76%

SummaryUpdated Jun 1, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a San Diego-based biopharmaceutical company founded in 1992 and publicly traded since 1996. The company specializes in developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. Originally focused on research and development, Neurocrine has evolved into a commercial-stage company with multiple marketed products and a robust pipeline of investigational therapies. The company has established itself as a leader in movement disorders and rare diseases, with its flagship product INGREZZA becoming a blockbuster treatment for tardive dyskinesia.

Ask drillr about NEUROCRINE BIOSCIENCES INC →

ValuationView details →

P/E (Fwd)

17.3x

P/E (TTM)

20.7x

EV/EBITDA

16.2x

EV/Sales

4.4x

P/S (TTM)

4.4x

P/B (TTM)

4.0x

ProfitabilityView details →

Gross Margin

97.97%

Net Margin

20.91%

EBITDA Margin

27.21%

ROE (TTM)

19.10%

ROA (TTM)

13.16%

Asset Turnover

0.66x

GrowthView details →

Revenue YoY

+34.42%

EPS YoY

+102.59%

FCF YoY

+64.63%

Revenue CAGR 3Y

+24.32%

EPS CAGR 3Y

+44.03%

EBITDA YoY

+60.76%

MomentumView details →

1D Return

−3.69%

YTD Return

+4.76%

1Y Return

+2.31%

RSI (14)

36.2

vs 50D SMA

−8.44%

vs 200D SMA

+0.43%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

1.87x

Quick Ratio

1.75x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.39

EPS Surprise

−15.76%

Beats (12Q)

4/12

Next Q EPS Est

$1.90

Avg Surprise (4Q)

6.88%

Rev Surprise

7.61%

Financials snapshotView financials →

Revenue (TTM)

3.37B

Net Income (TTM)

705.50M

Op. CF (TTM)

898.10M

Next earningsOct 27, 2026 →

Latest newsMore news →

Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.25d ago

Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.29d ago

Similar companies

Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK 华润江中600750.SH 海正药业600267.SH 九洲药业603456.SH 步长制药603858.SH 华润双鹤600062.SH Find similar companies →

Latest newsMore news →

Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.25d ago Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.29d ago